This article is more than 5 years old. Information may no longer be current.
OPTIMAX: Low MACE, no stent thrombosis at 12 months with novel stent
Patients with de novo coronary lesions implanted with a titanium-nitride-oxide–coated stent based on a cobalt chromium platform demonstrated adequate clinical outcomes, a low rate of MACE and no stent thrombosis, researchers reported in Catheterization and Cardiovascular Interventions.
The prospective study included 224 patients with symptomatic CAD and at least 50% stenosis of a de novo coronary lesion who underwent implantation with the Optimax (Hexacath) stent. The mean age of the patients was 67 years (75% men). Two-thirds of the cohort presented with ACS. Radial access was used for 92% of lesions.
The primary endpoint was MACE (cardiac mortality, nonfatal MI or ischemia-driven target lesion revascularization) at 12 months. The primary endpoint occurred in 6.3% of patients. Nonfatal MI was reported in 3.1% of patients, ischemia-driven TLR in 3.1% and cardiac death in 1.3%. The researchers observed no stent thrombosis.
The rates of procedural and clinical success were 100%.
“These results serve as hypothesis-generating and further results are needed to compare this novel stent design with new generation [drug-eluting stents],” the researchers wrote. – by Rob Volansky
Disclosure: The researchers report no relevant financial disclosures.